Skip to content
Medical Health Aged Care

Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET

Zomedica Corp. < 1 mins read

ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its third quarter ended September 30, 2023. A question-and-answer session will follow management's prepared remarks.

Event: Zomedica Q3 2023 Financial Results Conference Call
Date: Monday, November 13, 2023
Time: 4:30 p.m. Eastern Time
Live Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1641216&tp_key=4fcf4cae49

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Monday, November 27, 2023 at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13742390.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.



View source version on accesswire.com:
https://www.accesswire.com/798109/zomedica-to-report-third-quarter-2023-financial-results-and-provide-business-update-on-november-13-at-430-pm-et

More from this category

  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:
  • Medical Health Aged Care, Science
  • 17/12/2025
  • 07:56
Australian and New Zealand Journal of Public Health

Summer Mozzie Warning – Ross River Virus risk linked to warmer temperatures

17 December 2025 - Australians are being urged to prevent mosquito bites this summer, after research mapping studies from across the country found that warmer temperatures heighten the risk of Ross River Virus outbreaks, especially inriverland and coastal regions. The scoping review, led by the University of Adelaide, and published today in the Australian and New Zealand Journal of Public Health, also uncovered a knowledge gap when it comes to understanding the impact of temperature on Ross River Virus notifications within inland Australia. Ross River Virus is a common mosquito-borne diseases in Australia, with around 3,000 cases reported annually. It…

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.